Identification of blood-based biomarkers predictive of pulmonary exacerbations in cystic fibrosis
Individuals with cystic fibrosis experience recurrent episodes of worsen in respiratory symptoms, termed pulmonary exacerbations (PEx). Early identification of individuals who are at elevated risk of PEx can improve their clinical outcomes and rescue their lung function. In this project, we will collaborate with the Prevention of Organ Failure Centre of Excellence (PROOF) to develop a simple blood test to predict the PEx in CF individuals. We will also evaluate the genetic influence on blood biomarker candidates during the project and refine the blood test based on these genetic variants. Our interactions with PROOF Centre will directly benefit their organization by providing proof-of-concept of their goal, to develop blood-based biomarkers and move towards personalized medicine.